{
    "clinical_study": {
        "@rank": "131217", 
        "arm_group": {
            "arm_group_label": "Imaging", 
            "arm_group_type": "Experimental", 
            "description": "PET/MRI"
        }, 
        "brief_summary": {
            "textblock": "This study will use PET/MRI in patients with adenocarcinoma of the head of the pancreas to\n      identify hidden metastatic disease or identify patients with borderline or locally advanced\n      disease."
        }, 
        "brief_title": "Evaluation of PET/MRI in Patients With Pancreatic Adenocarcinoma", 
        "condition": "Adenocarcinoma Pancreas", 
        "condition_browse": {
            "mesh_term": "Adenocarcinoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Presence of suspicious lesion of the pancreas consistent with pancreatic\n             adenocarcinoma. Cytological confirmation is not required.\n\n          -  Patients preparing to receive therapy for pancreas cancer, including patients\n             enrolled in NCT01413022\n\n          -  Patient must be 18 years or older\n\n          -  Patient must have a life expectancy of more than 6 months and performance status of 2\n             or less\n\n          -  Patient must  have normal bone marrow and organ function as defined in protocol.\n\n          -  Patient must be able to understand and willing to sign an approved    written\n             informed consent document\n\n          -  Women of childbearing potential and men must agree to use adequate contraception\n             prior to study entry and for the length of the study\n\n          -  Patients enrolled in the Clinical trials.gov# NCT01413022 trial must meet both\n             studies eligibility criteria.\n\n        Exclusion Criteria:\n\n          -  Patient must not have had prior resection for pancreatic adenocarcinoma.\n\n          -  Patient must not have a history of other malignancy less than or equal to 5 years\n             previous with the exception of basal cell or squamous cell carcinoma of the skin\n             which were treated with local resection only or carcinoma in situ of the cervix\n\n          -  Patient must not be unable to receive a PET-MRI scan due to renal function, allergy\n             or other problem with receiving or tolerating an MRI scan, etc. All patients will\n             fill out a standard MRI screening form\n\n          -  Patients must not have a blood glucose of greater than or equal to 200mg/dL at the\n             time of PET-MRI or if a patient is diabetic and glucose is not controlled.\n\n          -  Patient must not be pregnant and/or breast feeding"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 23, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02028377", 
            "org_study_id": "201212004"
        }, 
        "intervention": {
            "arm_group_label": "Imaging", 
            "description": "PET/MRI", 
            "intervention_name": "PET/MRI", 
            "intervention_type": "Procedure"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Adenocarcinoma", 
            "imaging", 
            "PET", 
            "MRI"
        ], 
        "lastchanged_date": "April 15, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "St. Louis", 
                    "country": "United States", 
                    "state": "Missouri", 
                    "zip": "63110"
                }, 
                "name": "Washington Unviversity School of Medicine"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Evaluation of the Novel Imaging Modality Simultaneous Positron Emission Tomography Magnetic Resonance Imaging (PET/MRI) in Patients With Pancreatic Adenocarcinoma", 
        "overall_official": {
            "affiliation": "Washington University", 
            "last_name": "Ryan C. Fields, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Enrolling by invitation", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Primary outcome is to determine if the  primary tumor and the margins of anatomical land marks from the  PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI.  Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm.", 
            "measure": "PET/MRI compared to conventional CT and MRI", 
            "safety_issue": "No", 
            "time_frame": "Up to several months or longer. Patient will undergo research imaging with each standard of care scan they have."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02028377"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome is to determine if PET/MRI imaging is better than standard of care imaging (CT or MRI) after patients have received chemotherapy and to determine if they are surgical candidates. The objective is to determine if the primary tumor and the margins of anatomical land marks from the PET/MRI imaging is more precise and gives a clearer picture of tumor location than standard care, CT or MRI.  Both standard of care imaging and this new technology will be compared to the final pathologic analysis, measuring the true distance (in mm) between the primary tumor and margins. Data will be reported as mm.", 
            "measure": "Resectability post neoadjuvant treatment", 
            "safety_issue": "No", 
            "time_frame": "Several months or as deemed a surgical candidate by physician."
        }, 
        "source": "Washington University School of Medicine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Washington University School of Medicine", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}